Antizyme inhibitor 2 (AZIN2) takes part in the ornithine metabolic process and is identified to be an element for a poor prognosis in CRC, actuating aggressiveness of cancer cells with morphological characters of EMT (Kaprio et al., 2019). This evidence concerns the gene AZIN2 and colorectal carcinoma.